Singh, Jasvinder A. http://orcid.org/0000-0003-3485-0006
Funding for this research was provided by:
research funds from the Division of Rheumatology at the University of Alabama at Birmingham (No number)
resources and use of facilities at the Birmingham VA Medical Center, Birmingham, Alabama, USA (No number)
Article History
Received: 11 May 2018
Revised: 14 July 2018
Accepted: 25 July 2018
First Online: 4 August 2018
Compliance with ethical standards
:
: JAS has received research grants from Takeda and Savient pharmaceuticals and consultant fees from Savient, Takeda, Regeneron, Merz, Iroko, Bioiberica, Crealta/Horizon and Allergan pharmaceuticals, WebMD, UBM LLC, Medscape, Fidia pharmaceuticals, and the American College of Rheumatology. JAS serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA, Inc., a 501 (c) (3) entity. JAS is a member of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 36 companies; a member of the American College of Rheumatology’s (ACR) Annual Meeting Planning Committee (AMPC); Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is the editor and Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis.
: The University of Alabama at Birmingham’s Institutional Review Board approved this study (X120404005), and all investigations were conducted in conformity with ethical principles of research. All patients involved in the study including consent to participate in the study.